Studies on aminopenicillin developments. Proceedings of a symposium. Concluding remarks.
This symposium has focused on the bacteriological, pharmacokinetic, therapeutic, and adverse effects of the aminopenicillins. The compounds which are currently being assessed are primarily amoxycillin, ampicillin, bacampicillin, pivampicillin, and talampicillin. The three last mentioned are prodrugs which upon gastrointestinal absorption are rapidly split to yield circulating ampicillin. Pharmacokinetics and side-effects are reasons why one may narrow the selection of most suitable compounds within this group down to three. Ampicillin and amoxycillin are primary choices for parenteral dosage, and amoxycillin and bacampicillin the most suitable for oral therapy.
D000284:Administration, Oral; D000658:Amoxicillin / Q000627:therapeutic use*; D000667:Ampicillin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics
D000667:Ampicillin; D000658:Amoxicillin